Literature DB >> 3609187

Upper respiratory tract viral infection and mucociliary clearance.

R Wilson, E Alton, A Rutman, P Higgins, W Al Nakib, D M Geddes, D A Tyrrell, P J Cole.   

Abstract

Twenty-six normal volunteers were exposed to rhinovirus or influenza B virus. Measurement of nasal mucociliary clearance, ciliary beat frequency, percent of epithelium ciliated, ciliary ultrastructure and nasal transmucosal potential difference were made before exposure, during viral incubation and at the time of expected overt infection. Ten volunteers failed to become infected, six were subclinically infected and nine were infected with symptoms. There were no significant differences between the results in volunteer groups during the incubation period or between uninfected and subclinical groups at the time of expected symptoms. Six of nine symptomatic infected volunteers had prolonged nasal clearance, and six of the seven biopsied had less than 50% of their epithelium ciliated. However, there was no significant reduction in ciliary beat frequency nor increase in ultrastructural ciliary abnormalities within this group of symptomatic volunteers. Of the two symptomatic infected (influenza B) volunteers tested, both showed significantly reduced transmucosal potential difference.

Entities:  

Mesh:

Year:  1987        PMID: 3609187

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  20 in total

1.  Ciliary abnormalities in respiratory disease.

Authors:  R M Buchdahl; J Reiser; D Ingram; A Rutman; P J Cole; J O Warner
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

2.  Recovery of the ciliated epithelium following acute bronchiolitis in infancy.

Authors:  J Y W Wong; A Rutman; C O'Callaghan
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

3.  Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro.

Authors:  C Steinfort; R Wilson; T Mitchell; C Feldman; A Rutman; H Todd; D Sykes; J Walker; K Saunders; P W Andrew
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

4.  Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.

Authors:  F G Hayden; D L Kaiser; J K Albrecht
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

5.  Sec14l3 is specifically expressed in mouse airway ciliated cells.

Authors:  Lihua Shan; Shinobu Noritake; Masatoshi Fujiwara; Satoshi Asano; Chikako Yoshida-Noro; Nobuhiro Noro; Keizo Yamashita; Takao Kawakami
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

6.  Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus.

Authors:  Ian C Davis; Eduardo R Lazarowski; Judy M Hickman-Davis; James A Fortenberry; Fu-Ping Chen; Xiaodong Zhao; Eric Sorscher; Lee M Graves; Wayne M Sullender; Sadis Matalon
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

7.  Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values.

Authors:  Rogier R Jansen; Joanne Wieringa; Sylvie M Koekkoek; Caroline E Visser; Dasja Pajkrt; Richard Molenkamp; Menno D de Jong; Janke Schinkel
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

8.  Measurement of nasal mucociliary clearance.

Authors:  G M Corbo; A Foresi; P Bonfitto; A Mugnano; N Agabiti; P J Cole
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

9.  Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro.

Authors:  R Wilson; R Read; M Thomas; A Rutman; K Harrison; V Lund; B Cookson; W Goldman; H Lambert; P Cole
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Inflammatory hydrocephalus.

Authors:  Stephanie M Robert; Benjamin C Reeves; Arnaud Marlier; Phan Q Duy; Tyrone DeSpenza; Adam Kundishora; Emre Kiziltug; Amrita Singh; Garrett Allington; Seth L Alper; Kristopher T Kahle
Journal:  Childs Nerv Syst       Date:  2021-06-23       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.